Rezolute (RZLT) Other financing activities (2012 - 2026)

Rezolute (RZLT) posted Other financing activities of $747000.0 for Q1 2026, up 109.83% sequentially from $356000.0 in Q4 2025.

Rezolute (RZLT) Other financing activities (2012 - 2026) Analysis & Trends

Rezolute has reported Other financing activities for 7 years, with the latest figure at $747000.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $747000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 65.68% YoY) and the FY2025 annual result came in at $893000.0, up 281.62% from the prior year.
Other financing activities climbed to $747000.0 in Q1 2026 per RZLT's latest filing, from $356000.0 in the prior quarter.
Over five years, Other financing activities peaked at $12.3 million in Q3 2022 and troughed at $9997.0 in Q2 2025.
A 4-year average of $3.4 million and a median of $846500.0 in 2025 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 84.23% in 2025, down 84.23% in 2025.
Over 4 years, Other financing activities stood at $12.3 million in 2022, then plunged by 51.34% to $6.0 million in 2024, then sank by 94.07% to $356000.0 in 2025, then soared by 109.83% to $747000.0 in 2026.
According to Business Quant data, Other financing activities over the past three periods registered $747000.0, $356000.0, and $946000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Rezolute	442.94 Mn	442.94 Mn	-

Download Data